Target Name: MAGED2
NCBI ID: G10916
Review Report on MAGED2 Target / Biomarker Content of Review Report on MAGED2 Target / Biomarker
MAGED2
Other Name(s): MAGE-D2 antigen | breast cancer-associated gene 1 protein | MAGD2_HUMAN | MAGE family member D2, transcript variant 1 | melanoma antigen family D, 2 | MAGED2 variant 1 | HCA10 | MAGE family member D2 | Breast cancer-associated gene 1 protein | BCG-1 | MAGE-D2 | BARTS5 | Melanoma-associated antigen D2 | Hepatocellular carcinoma-associated protein JCL-1 | 11B6 | hepatocellular carcinoma-associated protein JCL-1 | BCG1 | melanoma antigen family D2

MAGED2: A Potential Drug Target and Biomarker

MAGE-D2 antigen, also known as MAGED2, is a protein that is expressed in various tissues and cells of the human body. It is a member of the MAGED family of proteins, which are involved in the development and maintenance of immune responses. MAGE -D2 antigen has been shown to play a role in the regulation of T cell responses and has potential as a drug target or biomarker.

MAGE-D2 antigen is expressed in a variety of tissues, including the skin, hair, and nails. It is also found in the gastrointestinal tract, where it has been shown to be involved in the regulation of immune responses. MAGE-D2 antigen has has been shown to be expressed in immune cells, including T cells, B cells, and natural killer cells. It is also expressed in the skin and hair, which may be important for its role in immune homeostasis.

One of the key functions of MAGE-D2 antigen is its role in the regulation of T cell responses. T cells are a critical part of the immune system, responsible for cell-mediated immunity against viruses, bacteria, and other pathogens. MAGE-D2 Antigen has been shown to play a role in the regulation of T cell responses by controlling the activation and proliferation of these cells.

MAGE-D2 antigen has also been shown to have potential as a drug target. Its involvement in the regulation of T cell responses makes it a potential target for small molecules that can modulate these responses. One approach to targeting MAGE-D2 antigen is to use inhibitors of the PI3K/Akt signaling pathway, which is a key pathway that is involved in the regulation of T cell responses.

In addition to its potential as a drug target, MAGE-D2 antigen has also been shown to be a potential biomarker. Its expression has been shown to be associated with various diseases, including autoimmune diseases, cancer, and neurodegenerative diseases. has also been shown to be expressed in the brains of individuals with Alzheimer's disease, which may be important for understanding the role of this protein in the development of this debilitating disease.

Overall, MAGE-D2 antigen is a protein that has important roles in the regulation of immune responses and in the development of various diseases. Its potential as a drug target and biomarker make it an attractive target for research into the underlying mechanisms of these processes. Further studies are needed to fully understand the role of MAGE-D2 antigen in the immune system and its potential as a drug or biomarker.

Protein Name: MAGE Family Member D2

Functions: Regulates the expression, localization to the plasma membrane and function of the sodium chloride cotransporters SLC12A1 and SLC12A3, two key components of salt reabsorption in the distal renal tubule

The "MAGED2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MAGED2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MAGED4 | MAGED4B | MAGEE1 | MAGEE2 | MAGEF1 | MAGEH1 | MAGEL2 | MAGI1 | MAGI1-AS1 | MAGI1-IT1 | MAGI2 | MAGI2-AS3 | MAGI3 | MAGIX | MAGOH | MAGOH-DT | MAGOHB | MAGT1 | MAIP1 | MAJIN | Major histocompatibility complex (MHC) antigen | Major Histocompatibility Complex Class I | Major histocompatibility complex class II antigens | MAK | MAK16 | MAL | MAL2 | MALAT1 | Malate dehydrogenase | MALL | MALLP2 | MALRD1 | MALSU1 | MALT1 | MAMDC2 | MAMDC2-AS1 | MAMDC4 | MAML1 | MAML2 | MAML3 | MAMLD1 | MAMSTR | MAN1A1 | MAN1A2 | MAN1B1 | MAN1B1-DT | MAN1C1 | MAN2A1 | MAN2A2 | MAN2B1 | MAN2B2 | MAN2C1 | MANBA | MANBAL | MANCR | MANEA | MANEA-DT | MANEAL | MANF | MANSC1 | MANSC4 | MAOA | MAOB | MAP10 | MAP1A | MAP1B | MAP1LC3A | MAP1LC3B | MAP1LC3B2 | MAP1LC3BP1 | MAP1LC3C | MAP1S | MAP2 | MAP2K1 | MAP2K1P1 | MAP2K2 | MAP2K3 | MAP2K4 | MAP2K4P1 | MAP2K5 | MAP2K6 | MAP2K7 | MAP3K1 | MAP3K10 | MAP3K11 | MAP3K12 | MAP3K13 | MAP3K14 | MAP3K14-AS1 | MAP3K15 | MAP3K19 | MAP3K2 | MAP3K2-DT | MAP3K20 | MAP3K20-AS1 | MAP3K21 | MAP3K3 | MAP3K4 | MAP3K5 | MAP3K5-AS2